While no companies are scheduled to go public in the week ahead, several companies could join the IPO calendar. Potential Launches include health clinic chain One Medical (ONEM), DTC mattress unicorn Casper (CSPR), and...read more
The IPO market’s annual August break is here, with no companies scheduled to go public in the week ahead, save for one holdover from last week that may price: Chinese AR play WiMi Hologram (WIMI). The summer slowdown is almost over, and...read more
Eight companies and two SPACs entered the public market this week. Health and tech companies Health Catalyst, Castle Biosciences, and Livongo dominated while solar energy installer Sunnova and sporting events company Wanda Sports Group fell flat. read more
Castle Biosciences, which sells genetic tests used to diagnose skin cancers, raised $64 million by offering 4.0 million shares at $16, the high end of the range of $14 to $16. The company sold an additional 0.67 million shares on the offering. Insiders had...read more
US IPO Week Ahead: No IPOs in the shortened holiday week
While no companies are scheduled to go public in the week ahead, several companies could join the IPO calendar. Potential Launches include health clinic chain One Medical (ONEM), DTC mattress unicorn Casper (CSPR), and...read more
US IPO Week Ahead: IPO filings heat up amid annual August break
The IPO market’s annual August break is here, with no companies scheduled to go public in the week ahead, save for one holdover from last week that may price: Chinese AR play WiMi Hologram (WIMI). The summer slowdown is almost over, and...read more
US IPO Weekly Recap: Health-tech tops 8-IPO week
Eight companies and two SPACs entered the public market this week. Health and tech companies Health Catalyst, Castle Biosciences, and Livongo dominated while solar energy installer Sunnova and sporting events company Wanda Sports Group fell flat.read more
Skin cancer test provider Castle Biosciences prices upsized IPO at the $16 high end
Castle Biosciences, which sells genetic tests used to diagnose skin cancers, raised $64 million by offering 4.0 million shares at $16, the high end of the range of $14 to $16. The company sold an additional 0.67 million shares on the offering. Insiders had...read more